

# Gilles Montalescot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7575716/publications.pdf>

Version: 2024-02-01

127  
papers

17,916  
citations

101543

36  
h-index

17105

122  
g-index

128  
all docs

128  
docs citations

128  
times ranked

15727  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2022, 43, e17-e25.	2.2	92
2	How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. <i>Panminerva Medica</i> , 2022, 64, .	0.8	4
3	Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13664.	3.4	3
4	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 96-96.	1.6	1
5	Postprocedure Anticoagulation in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 251-263.	2.9	3
6	Outcomes Following Patent Foramen Ovale Percutaneous Closure According to the Delay From Last Ischemic Event. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1228-1234.	1.7	6
7	ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 633-643.	3.0	8
8	Economic evaluation of fractional flow reserve-guided versus angiography-guided multivessel revascularisation in ST-segment elevation myocardial infarction patients in the FLOWER-MI randomised trial. <i>EuroIntervention</i> , 2022, 18, 235-241.	3.2	5
9	Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. <i>European Heart Journal</i> , 2022, 43, 2783-2797.	2.2	74
10	2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 324-333.	3.0	22
11	Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 225-235.	3.0	40
12	Life-threatening and major cardiac events during long-distance races: updates from the prospective RACE PARIS registry with a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 679-686.	1.8	12
13	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial. <i>Chest</i> , 2021, 159, 1415-1425.	0.8	4
14	Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data. <i>European Heart Journal</i> , 2021, 42, 323-334.	2.2	68
15	Coronavirus Disease 2019-associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management. <i>Journal of the American Heart Association</i> , 2021, 10, e019650.	3.7	122
16	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2021, 324, 30-37.	1.7	4
17	Predictive Value of the Residual SYNTAX Score in Patients With Cardiogenic Shock. <i>Journal of the American College of Cardiology</i> , 2021, 77, 144-155.	2.8	19
18	Impact of chronic total occlusion and revascularization strategy in patients with infarct-related cardiogenic shock: A subanalysis of the culprit-shock trial. <i>American Heart Journal</i> , 2021, 232, 185-193.	2.7	13

#	ARTICLE	IF	CITATIONS
19	Should Hemoglobin Drop Be Added to Bleeding Classifications in ACS?. Journal of the American College of Cardiology, 2021, 77, 389-391.	2.8	3
20	Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROCR-DRT-Registry. Circulation: Cardiovascular Interventions, 2021, 14, e010195.	3.9	46
21	Reply. Journal of the American College of Cardiology, 2021, 77, 2872-2873.	2.8	0
22	Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2021, 14, 1323-1333.	2.9	5
23	Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial. American Journal of Cardiovascular Drugs, 2021, 21, 681-691.	2.2	4
24	Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. New England Journal of Medicine, 2021, 385, 297-308.	27.0	172
25	Compared Outcomes of ST-Segment Elevation Myocardial Infarction Patients With Multivessel Disease Treated With Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Nonculprit Lesions Treated Conservatively and of Those With Low Fractional Flow Reserve Managed Invasively: Insights From the FLOWER-MI Trial. Circulation: Cardiovascular Interventions, 2021, 14, e011214.	3.9	20
26	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 1688-1703.	2.9	31
27	Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. Journal of the American Heart Association, 2021, 10, e020446.	3.7	7
28	Comparison of risk prediction models in infarct-related cardiogenic shock. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 890-897.	1.0	11
29	Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT-SHOCK Substudy. Journal of the American Heart Association, 2021, 10, e021150.	3.7	1
30	Head-to-head comparison of the diagnostic performances of Rubidium-PET and SPECT with CZT camera for the detection of myocardial ischemia in a population of women and overweight individuals. Journal of Nuclear Cardiology, 2020, 27, 755-768.	2.1	14
31	Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial. American Journal of Cardiovascular Drugs, 2020, 20, 61-71.	2.2	22
32	Cardiovascular manifestations of sickle cell disease. European Heart Journal, 2020, 41, 1365-1373.	2.2	25
33	Predictors of Left Ventricular Dysfunction in Friedreich's Ataxia in a 16-Year Observational Study. American Journal of Cardiovascular Drugs, 2020, 20, 209-216.	2.2	7
34	Rationale and design of the Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction (FLOWER-MI) trial. American Heart Journal, 2020, 222, 1-7.	2.7	13
35	Do we need a new P2Y12 receptor antagonist?. European Heart Journal, 2020, 41, 3141-3143.	2.2	6
36	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. Thrombosis and Haemostasis, 2020, 120, 065-074.	3.4	11

#	ARTICLE	IF	CITATIONS
37	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 179.	6.8	14
38	Interleukin-1 $\beta$ and Risk of Premature Death in Patients With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1763-1773.	2.8	23
39	Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 2316-2328.	1.6	26
40	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 76, 486-487.	2.8	0
41	Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008481.	3.9	35
42	Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. <i>Lancet</i> , 2020, 396, 1737-1744.	13.7	75
43	Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 797-810.	1.6	7
44	Effects of ON-Hours Versus OFF-Hours Admission on Outcome in Patients With Myocardial Infarction and Cardiogenic Shock. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009562.	3.9	5
45	Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study. <i>American Heart Journal</i> , 2020, 225, 27-37.	2.7	6
46	Acute Multivessel Coronary Occlusion Revealing COVID-19 in a Young Adult. <i>JACC: Case Reports</i> , 2020, 2, 1297-1301.	0.6	10
47	Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2020, 227, 19-30.	2.7	3
48	Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 680.	2.4	9
49	Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008537.	3.9	35
50	Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial. <i>American Heart Journal</i> , 2020, 225, 60-68.	2.7	16
51	Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 860.	2.4	8
52	COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. <i>American Heart Journal</i> , 2020, 224, 10-16.	2.7	12
53	Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1676-1685.	2.8	124
54	Prognostic Value of SYNTAX Score in Patients With Infarct-Related Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1198-1206.	2.9	12

#	ARTICLE	IF	CITATIONS
55	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	2.2	4,537
56	Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007749.	3.9	2
57	Interventional Standby for CABG Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 73, 424-426.	2.8	1
58	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 200-206.	3.0	25
59	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 680.	6.1	9
60	Left Atrial Appendage Closure. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1077-1079.	2.9	1
61	Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2401-2409.	2.8	69
62	Kidney in the transformation matrix. <i>European Heart Journal</i> , 2019, 40, 1233-1235.	2.2	2
63	Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach. <i>Drugs and Aging</i> , 2019, 36, 531-539.	2.7	16
64	Anticoagulation, the Unknown of the Antithrombotic Equation After Stenting of an Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 73, 775-778.	2.8	3
65	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. <i>American Heart Journal</i> , 2019, 212, 13-22.	2.7	13
66	Epidemiology, treatment patterns and outcomes in patients with coronary or lower extremity artery disease in France. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 670-679.	1.6	8
67	Best Practices for the Prevention of Radial Artery Occlusion After Transradial Diagnostic Angiography and Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2235-2246.	2.9	111
68	Copeptin as a prognostic biomarker in acute myocardial infarction. <i>International Journal of Cardiology</i> , 2019, 274, 337-341.	1.7	19
69	A farewell to aspirin in primary prevention?. <i>Nature Reviews Cardiology</i> , 2019, 16, 76-77.	13.7	3
70	Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use. <i>Journal of the American College of Cardiology</i> , 2019, 73, 13-21.	2.8	85
71	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 173-183.	2.2	23
72	Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E369-E377.	1.7	4

#	ARTICLE	IF	CITATIONS
73	Long-Term Evolution of Premature Coronary Artery Disease. Journal of the American College of Cardiology, 2019, 74, 1868-1878.	2.8	81
74	The times they are a changin'1. European Heart Journal, 2018, 39, 1736-1739.	2.2	3
75	Periprocedural myocardial infarction and injury in elective coronary stenting. European Heart Journal, 2018, 39, 1100-1109.	2.2	136
76	Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. American Heart Journal, 2018, 200, 44-50.	2.7	111
77	Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial. American Heart Journal, 2018, 196, 1-8.	2.7	4
78	Mineralocorticoid receptor antagonists in patients with acute myocardial infarction – A systematic review and meta-analysis of randomized trials. American Heart Journal, 2018, 195, 60-69.	2.7	21
79	The false illusion of coronary thrombus device-management. Journal of Thoracic Disease, 2018, 10, S4117-S4121.	1.4	0
80	Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment. TH Open, 2018, 02, e357-e368.	1.4	3
81	Coronary Artery Bypass Graft Surgery Guided by FFR. Journal of the American College of Cardiology, 2018, 72, 2744-2746.	2.8	2
82	Association of Serum Cholesterol Efflux Capacity With Mortality in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2018, 72, 3259-3269.	2.8	55
83	Age and benefit of early coronary angiography after out-of-hospital cardiac arrest in patients presenting with shockable rhythm: Insights from the Sudden Death Expertise Center registry. Resuscitation, 2018, 128, 126-131.	3.0	20
84	One-Year Outcomes after PCI Strategies in Cardiogenic Shock. New England Journal of Medicine, 2018, 379, 1699-1710.	27.0	303
85	Can a stable coronary artery disease patient be at high ischaemic risk for scheduled non-cardiac surgery?. Anaesthesia, Critical Care & Pain Medicine, 2018, 37, 313-315.	1.4	0
86	Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention. Angiology, 2017, 68, 29-39.	1.8	10
87	Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENTâ€HF randomized phase 2 trial. European Journal of Heart Failure, 2017, 19, 1534-1541.	7.1	75
88	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. New England Journal of Medicine, 2017, 376, 1933-1942.	27.0	593
89	Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 198-213.	3.0	18
90	PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. New England Journal of Medicine, 2017, 377, 2419-2432.	27.0	764

#	ARTICLE	IF	CITATIONS
91	Association between gender and short-term outcome in patients with ST elevation myocardial infarction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis. <i>BMI Open</i> , 2017, 7, e015241.	1.9	27
92	Efficacy and Safety of Ticagrelor OverTime in Patients With Prior MI inPEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1368-1375.	2.8	74
93	DoubleDose Versus StandardDose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	9
94	Intravenous enoxaparin anticoagulation in percutaneous left atrial cardiac procedures. <i>EuroIntervention</i> , 2017, 13, 1226-1233.	3.2	7
95	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. <i>International Journal of Cardiology</i> , 2016, 218, 291-297.	1.7	8
96	Early Aldosterone Blockade in AcuteMyocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1917-1927.	2.8	86
97	Individualized Modeling Approach forADAPT Duration. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2235-2236.	2.8	0
98	Cangrelor. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1914-1916.	2.9	1
99	Cerebral Embolism. <i>Journal of the American College of Cardiology</i> , 2016, 68, 600-602.	2.8	10
100	Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. <i>Lancet, The</i> , 2016, 388, 2015-2022.	13.7	303
101	Prasugrel versus clopidogrel in acute coronary syndromes treated with PCI: Effects on clinical outcome according to culprit artery location. <i>International Journal of Cardiology</i> , 2016, 223, 632-638.	1.7	5
102	The Triple Challenge of Triple Therapy. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1703-1705.	2.9	1
103	Clinical Outcome of Firstvs SecondGeneration DES According to DAPT Duration: Results of ARCTIC Generation. <i>Clinical Cardiology</i> , 2016, 39, 192-200.	1.8	7
104	Potent P2Y 12 Inhibitors in Low-Risk Patients. <i>Journal of the American College of Cardiology</i> , 2016, 67, 614-617.	2.8	3
105	Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 152-167.	3.0	50
106	P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 229-243.	3.0	46
107	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. <i>American Heart Journal</i> , 2016, 172, 160-169.	2.7	93
108	Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 43-53.	2.2	4

#	ARTICLE	IF	CITATIONS
109	Platelet Function Testâ€“Guided Strategy. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002716.	3.9	1
110	Efficacy of Ex Vivo Autologous and In Vivo Platelet Transfusion in the Reversal of P2Y <sub>12</sub> Inhibition by Clopidogrel, Prasugrel, and Ticagrelor. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002786.	3.9	59
111	Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 502-510.	1.6	8
112	Angiotensin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow. <i>International Journal of Cardiology</i> , 2015, 187, 511-516.	1.7	18
113	Sex-related differences after contemporary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 428-436.	1.6	17
114	Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial. <i>American Heart Journal</i> , 2015, 170, 778-786.	2.7	9
115	Dual antiplatelet therapy: optimal timing, management, and duration. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 198-204.	3.0	32
116	Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1315-1324.	1.9	31
117	Microparticles and sudden cardiac death due to coronary occlusion. <i>The TIDE (Thrombus and) Tj ETQq1 1 0.784314 rgBT /Overlock 10</i> 28-36.	1.0	39
118	Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. <i>BMJ</i> , The, 2014, 347, g6269-g6269.	6.0	75
119	Pretreatment with P2Y <sub>12</sub> Inhibitors in Nonâ€“ST-Segmentâ€“Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy. <i>Circulation</i> , 2014, 130, 1904-1914.	1.6	36
120	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	2.2	4,141
121	Î²-Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 872-881.	2.2	84
122	Pretreatment with P2Y <sub>12</sub> inhibitors in nonâ€“ST-segment elevation acute coronary syndrome: Time to revise the guidelines?. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 1-3.	1.6	1
123	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1982-1988.	2.8	752
124	A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2006, 48, 931-938.	2.8	509
125	STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). <i>European Heart Journal</i> , 2006, 28, 1409-1417.	2.2	258
126	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. <i>New England Journal of Medicine</i> , 2006, 354, 1706-1717.	27.0	2,582



#	ARTICLE	IF	CITATIONS
127	Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or nonâ€“ST-segment elevation acute myocardial infarction (the ARMADA study). American Journal of Cardiology, 2003, 91, 925-930.	1.6	79